GLP-1 side effects, and how they’re managed
Most side effects are gut-related, usually mild, and often manageable. Here’s what to expect — and when to seek care.
By The Vive Team
July 2026 · 7 min read
No medicine is free of side effects, and being told the truth about them up front is part of good care. With GLP-1 medicines, the most common effects are predictable, mostly gastrointestinal, and often ease with time and sensible adjustments.
The common, usually mild ones
Because GLP-1 slows the stomach, the most frequent side effects are digestive:
- nausea — the most common, especially in the first weeks and after a dose increase;
- vomiting, diarrhoea or constipation;
- reflux, bloating or a feeling of fullness.
For most people these are mild to moderate and settle as the body adjusts. They are also the main reason doses are started low and raised slowly.
What actually helps
Clinicians and patients consistently find a few things reduce the gut effects: eating smaller portions, stopping when comfortably full rather than stuffed, easing off very fatty or very large meals, and staying hydrated. If side effects are hard to tolerate, the answer is often a slower titration or holding a dose — not pushing through. This is exactly the kind of adjustment your care team is there for.
The uncommon but serious ones
Rarely, GLP-1 medicines are associated with more serious problems — pancreatitis, gallbladder disease, and severe allergic reactions. Seek urgent medical care for severe or persistent abdominal pain (which can radiate to the back), signs of an allergic reaction, or symptoms of gallbladder trouble. Tell your physician about all your medicines and conditions before starting, and read the Important Safety Information in full.
The bottom line
Side effects are common but usually manageable, and serious ones are rare. The point of ongoing clinical review is to catch problems early and adjust — which is why this is prescription-only care, not a product you take alone.
// References
- 1.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. View study →
- 2.Product prescribing information for GLP-1 receptor agonists (adverse reactions; warnings for pancreatitis and gallbladder disease).
Provided for education only. Trial averages describe study populations, not any individual’s expected result. This is not medical advice — GLP-1 medication is prescription-only and outcomes vary.
Medically reviewed by Vive’s licensed physicians. Meet the clinicians →
Curious what’s right for you?
Take the 3-min quiz →